focus -WSS

focus

author：comprehensive 2025-09-27 23:11:49 - browse：6

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： WHO recommends dropping component of many flu vaccines

WSS

Researchers use wearables data and AI to predict preterm birth risk

How one patient went off dialysis — and others can too

Goldman Sachs launches $650M fund for life science investments

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

AdventHealth escalates lawsuit against insurance vendor Multiplan

leisure time

focus

entertainment

In age of alternative facts, a scholarly course on calling out crap

AdventHealth escalates lawsuit against insurance vendor Multiplan

In age of alternative facts, a scholarly course on calling out crap

WHO recommends dropping component of many flu vaccines

Hollywood unions extend contract negotiations for actors

JPM: CVS says Medicare Advantage patients are impacting profits

As demand for Covid shots wanes, Moderna seeks its next success

Did you have Obamacare on your GOP debate bingo card?

How one medical school became remarkably diverse

How one patient went off dialysis — and others can too

hotspot

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Feng Zhang, Grail founder join forces on new gene editing startup

WHO recommends dropping component of many flu vaccines

Medicaid, Medicare dual

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

hotspot

leisure time

hotspot

leisure time